Abbreviations: ASCT, autologous stem cell transplantation; C, cycle; CD, cluster of differentiation; CR, complete response; CTCAE, Common Terminology Criteria for Adverse Events; D, daratumumab; d, dexamethasone; D-VTd, daratumumab + bortezomib + thalidomide + dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; HDT, high-dose chemotherapy; IV, intravenous; MM, multiple myeloma; MRD, minimal residual disease; NGS, Next-generation sequencing; ORR, overall response rate; OS, overall survival; PCD, plasma cell dyscrasia; PCL, plasma cell leukemia; PD, progressive disease; PFS, progression-free survival; PFS2, PFS after the next line of therapy; PO, per oral; PR, partial response; QW, once a week; Q2W, every 2 weeks; Q8W, every 8 weeks; SC, subcutaneous; sCR, stringent complete response; T, thalidomide; TTP, time to progression; V, bortezomib; VTd, bortezomib + thalidomide + dexamethasone.
^aMoreau (2019)¹. ^bMoreau (2021)². ^cBegan after hematopoietic reconstitution but not earlier than 30 days after transplant. ^dDaratumumab or other anti-CD38 therapies. ^eIn patients with CR at a threshold of 10^-5 by NGS.

Abbreviations: ASCT, autologous stem cell transplantation; D-VTd, daratumumab + bortezomib + thalidomide + dexamethasone; IRRs, infusion related reactions; IV, intravenous.
^fData on file (2019).³